Research programme: inflammation therapy - BioLineRxAlternative Names: BL-3030
Latest Information Update: 04 Feb 2008
At a glance
- Originator Ben Gurion University
- Developer BioLineRx
- Mechanism of Action Phospholipase A2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Feb 2008 No development reported - Preclinical for Inflammation in Israel (unspecified route)
- 02 Oct 2006 Preclinical trials in Inflammation in Israel (unspecified route)